Background: Glycine dehydrogenase(GLDC) plays an important role in the initiation and proliferation of several human cancers. In this study, we aimed to detect the methylation status of GLDC promoter and its diagnosti...Background: Glycine dehydrogenase(GLDC) plays an important role in the initiation and proliferation of several human cancers. In this study, we aimed to detect the methylation status of GLDC promoter and its diagnostic value for hepatitis B virus-associated hepatocellular carcinoma(HBV-HCC). Methods: We enrolled 197 patients, 111 with HBV-HCC, 51 with chronic hepatitis B(CHB), and 35 healthy controls(HCs). The methylation status of GLDC promoter in peripheral mononuclear cells(PBMCs) was identified by methylation specific polymerase chain reaction(MSP). The mRNA expression was examined using real-time quantitative polymerase chain reaction(q PCR). Results: The methylation frequency of the GLDC promoter was significantly lower in HBV-HCC patients(27.0%) compared to that in CHB patients(68.6%) and HCs(74.3%)( P < 0.001). The methylated group had lower alanine aminotransferase level( P = 0.035) and lower rates of tumor node metastasis(TNM) Ⅲ/Ⅳ( P = 0.043) and T3/T4( P = 0.026). TNM stage was identified to be an independent factor for GLDC promoter methylation. GLDC mRNA levels in CHB patients and HCs were significantly lower than those in HBV-HCC patients( P = 0.022 and P < 0.001, respectively). GLDC mRNA levels were significantly higher in HBV-HCC patients with unmethylated GLDC promoters than those with methylated GLDC promoters( P = 0.003). The diagnostic accuracy of alpha-fetoprotein(AFP) combined with GLDC promoter methylation for HBV-HCC was improved compared with that of AFP alone(AUC: 0.782 vs. 0.630, P < 0.001). In addition, GLDC promoter methylation was an independent predictor for overall survival of HBV-HCC patients( P = 0.038). Conclusions: The methylation frequency of GLDC promoter was lower in PBMCs from HBV-HCC patients than that from patients with CHB and HCs. The combination of AFP and GLDC promoter hypomethylation significantly improved the diagnostic accuracy of HBV-HCC.展开更多
Objective Isocitrate dehydrogenase gene(IDH)mutations are associated with tumor angiogenesis and therefore play an important role in glioma management.This study compared the performance of tumor blood vessels counted...Objective Isocitrate dehydrogenase gene(IDH)mutations are associated with tumor angiogenesis and therefore play an important role in glioma management.This study compared the performance of tumor blood vessels counted from contrast-enhanced 3D brain volume(3D-BRAVO)sequence and dynamic contrast-enhanced(DCE)MRI in differentiating IDH1 status in gliomas.Methods Forty-four glioma patients[16 with IDH1 mutant-type(IDH1-MT),28 with IDH1 wild-type(IDH1-WT)]were retrospectively analyzed.A blood vessel entering a tumor was defined as an intratumoral vessel;a blood vessel adjacent to the edge of a tumor was defined as a peritumoral vessel.Combined vessels were defined as the sum of the intratumoral and peritumoral vessels.DCE-derived metrics of tumor were normalized to the contralateral normal-appearing white matter.Results Intratumoral,peritumoral,and combined tumor blood vessels were all significantly different between IDH1-MT and IDH1-WT gliomas,and the range of area under curves(AUCs)was 0.816–0.855.For DCE-derived parameters,cerebral blood volume,cerebral blood flow,mean transit time,and volume transfer constant were significantly different between IDH1-MT and IDH1-WT gliomas,and the range of AUCs was 0.703–0.756.Combined vessels possessed the best performance for identifying IDH1 mutations in gliomas(AUC:0.855,sensitivity:0.857,specificity:0.812,P<0.001).Conclusion The number of tumor blood vessels has comparable diagnostic performance with DCE-derived parameters for differentiating IDH1 mutations and can serve as a potential imaging biomarker to reflect IDH1 mutations in gliomas.展开更多
We studied the metabolic changes induced by gaseous nitric oxide in whole blood samples in vitro. Blood samples were collected from healthy donors (Nizhny Novgorod station of blood transfusion). We carried out the dir...We studied the metabolic changes induced by gaseous nitric oxide in whole blood samples in vitro. Blood samples were collected from healthy donors (Nizhny Novgorod station of blood transfusion). We carried out the direct bubbling of blood samples (n = 14) with gaseous flow with NO in a special appliance. We modeled standard conditions using the apparatus “Plazon” (concentration NO 800 mcg/l). Middle power of gas flow was used. The blood sparging time was 2 min, and exposition time lasted 3 min. Every blood sample volume was 5 ml. All the parameters were controlled before and after blood processing with NO. We tested lactate dehydrogenase activity in direct and reverse reactions spectrometrically by G. A. Kochetov’s method. Aldehyde dehydrogenase activity was examined by B. M. Kershnhots’s and E. V. Serkina’s methods, superoxide dismutase—by T. V. Sirota’s technology. Total protein level was examined by modified Louri’s method. The concentration of lactate was tested with the automatic analyzer “SuperGL Ambulance”. The indices of acidbase balance and blood gases partial pressure were estimated with special analyzer “ABL-77”. Additional control of energy metabolism changes was accomplished with derivative parameters, such as coefficient of energy reaction balance and coefficient of substrate provision. Different changes of blood physical and chemical parameters are induced by NO-processing which was fixed in our experiments. There is an inhibition of erythrocytes energy metabolism, decreasing of plasma antioxidant reserves, moderate ionic disorders and of acid-base misbalance in blood samples in vitro. Besides, according to the indirect signs, the used regimen of NO-processing mainly affected erythrocytes, and stipulated methemoglobin formation. These data testify that the used dose of gaseous nitric oxide is too high for investigated human blood. In our opinion, registered negative effects of free NO may be eliminated by bound nitric oxide use (first of all in its natural form—dinitrosyl-iron complexes).展开更多
AIM:To study frequency of blood groups,prevalence of sickle-cell anemia trait and glucose-6-phosphate dehydrogenase deficiency(G6PD),among consanguineous Yansi tribe.METHODS:A total of 525 blood samples were collected...AIM:To study frequency of blood groups,prevalence of sickle-cell anemia trait and glucose-6-phosphate dehydrogenase deficiency(G6PD),among consanguineous Yansi tribe.METHODS:A total of 525 blood samples were collected,of which 256 among the Yansi population,and269 for the unrelated control group in the Bandunduprovince of Democratic Republic of Congo.Blood group antigens were determined in the following systems:ABO,Rh,Kell,Duffy,Kidd and MNS.Blood grouping and extended phenotype tests were performed according to standard immunohematological procedures.Spot tests and tandem mass spectrometry were used respectively for the assessment of G6PD and sickle-cell anemia trait.RESULTS:The frequency of ABO phenotypes conformed to the following order O>A>B>AB with notably 62.5%,23.8%,12.1%and 1.6%for the Yansi,and 54.6%,27.5%,14.1%and 3.7%for the unrelated control group,respectively(P=0.19).As for the Rh phenotypes,the most frequent were cc D.ee,cc D.Ee,Cc D.ee,corresponding to 71.5%,12.1%and 12.1%for the Yansi,and 70.6%,15.6%and 8.2%,for the unrelated control group(P=0.27).The frequency of MN and Ss phenotypes were statistically different between groups(P=0.0021 and P=0.0006).G6PD was observed in 11.3%of subjects in the Yansi group,and in 12.4%of controls(P=0.74).The sickle-cell anemia trait was present in 22.4%of Yansi subjects and 17.8%in the control group(P=0.24).Miscarriages and deaths in young age were more common among Yansi people.CONCLUSION:This study shows a significant difference in MNS blood group distribution between the Yansi tribe and a control population.The distribution of other blood groups and the prevalence of hemoglobinopathies did not differ in the Yansi tribe.展开更多
目的初步探讨血镉及胎盘11β-羟基类固醇脱氢酶2(11β-hydroxysteroid dehydrogenase type 2,11β-HSD2)与重度子痫前期的相关性及镉与11β-HSD2参与重度子痫前期发生的机制。方法选取32例重度子痫前期妊娠孕妇为研究组及同期孕检正常孕...目的初步探讨血镉及胎盘11β-羟基类固醇脱氢酶2(11β-hydroxysteroid dehydrogenase type 2,11β-HSD2)与重度子痫前期的相关性及镉与11β-HSD2参与重度子痫前期发生的机制。方法选取32例重度子痫前期妊娠孕妇为研究组及同期孕检正常孕妇32例为正常妊娠组,测定2组孕妇血镉水平和胎盘中11β-HSD2表达水平。结果与正常妊娠组相比,研究组重金属镉水平升高,11β-HSD2表达降低(P<0.05)。结论血镉与11β-HSD2可能参与了重度子痫前期的发生发展。展开更多
基金This study was supported by grants from the Key Project of the Chinese Ministry of Science and Technology(2017ZX102022022)National Key Research and Development Program of China(2021YFC2301801).
文摘Background: Glycine dehydrogenase(GLDC) plays an important role in the initiation and proliferation of several human cancers. In this study, we aimed to detect the methylation status of GLDC promoter and its diagnostic value for hepatitis B virus-associated hepatocellular carcinoma(HBV-HCC). Methods: We enrolled 197 patients, 111 with HBV-HCC, 51 with chronic hepatitis B(CHB), and 35 healthy controls(HCs). The methylation status of GLDC promoter in peripheral mononuclear cells(PBMCs) was identified by methylation specific polymerase chain reaction(MSP). The mRNA expression was examined using real-time quantitative polymerase chain reaction(q PCR). Results: The methylation frequency of the GLDC promoter was significantly lower in HBV-HCC patients(27.0%) compared to that in CHB patients(68.6%) and HCs(74.3%)( P < 0.001). The methylated group had lower alanine aminotransferase level( P = 0.035) and lower rates of tumor node metastasis(TNM) Ⅲ/Ⅳ( P = 0.043) and T3/T4( P = 0.026). TNM stage was identified to be an independent factor for GLDC promoter methylation. GLDC mRNA levels in CHB patients and HCs were significantly lower than those in HBV-HCC patients( P = 0.022 and P < 0.001, respectively). GLDC mRNA levels were significantly higher in HBV-HCC patients with unmethylated GLDC promoters than those with methylated GLDC promoters( P = 0.003). The diagnostic accuracy of alpha-fetoprotein(AFP) combined with GLDC promoter methylation for HBV-HCC was improved compared with that of AFP alone(AUC: 0.782 vs. 0.630, P < 0.001). In addition, GLDC promoter methylation was an independent predictor for overall survival of HBV-HCC patients( P = 0.038). Conclusions: The methylation frequency of GLDC promoter was lower in PBMCs from HBV-HCC patients than that from patients with CHB and HCs. The combination of AFP and GLDC promoter hypomethylation significantly improved the diagnostic accuracy of HBV-HCC.
基金the National Natural Science Foundation of China(No.81730049 and No.81801666)the Fundamental Research Funds for the Central Universities,HUST(No.2019JYCXJJ044).
文摘Objective Isocitrate dehydrogenase gene(IDH)mutations are associated with tumor angiogenesis and therefore play an important role in glioma management.This study compared the performance of tumor blood vessels counted from contrast-enhanced 3D brain volume(3D-BRAVO)sequence and dynamic contrast-enhanced(DCE)MRI in differentiating IDH1 status in gliomas.Methods Forty-four glioma patients[16 with IDH1 mutant-type(IDH1-MT),28 with IDH1 wild-type(IDH1-WT)]were retrospectively analyzed.A blood vessel entering a tumor was defined as an intratumoral vessel;a blood vessel adjacent to the edge of a tumor was defined as a peritumoral vessel.Combined vessels were defined as the sum of the intratumoral and peritumoral vessels.DCE-derived metrics of tumor were normalized to the contralateral normal-appearing white matter.Results Intratumoral,peritumoral,and combined tumor blood vessels were all significantly different between IDH1-MT and IDH1-WT gliomas,and the range of area under curves(AUCs)was 0.816–0.855.For DCE-derived parameters,cerebral blood volume,cerebral blood flow,mean transit time,and volume transfer constant were significantly different between IDH1-MT and IDH1-WT gliomas,and the range of AUCs was 0.703–0.756.Combined vessels possessed the best performance for identifying IDH1 mutations in gliomas(AUC:0.855,sensitivity:0.857,specificity:0.812,P<0.001).Conclusion The number of tumor blood vessels has comparable diagnostic performance with DCE-derived parameters for differentiating IDH1 mutations and can serve as a potential imaging biomarker to reflect IDH1 mutations in gliomas.
文摘We studied the metabolic changes induced by gaseous nitric oxide in whole blood samples in vitro. Blood samples were collected from healthy donors (Nizhny Novgorod station of blood transfusion). We carried out the direct bubbling of blood samples (n = 14) with gaseous flow with NO in a special appliance. We modeled standard conditions using the apparatus “Plazon” (concentration NO 800 mcg/l). Middle power of gas flow was used. The blood sparging time was 2 min, and exposition time lasted 3 min. Every blood sample volume was 5 ml. All the parameters were controlled before and after blood processing with NO. We tested lactate dehydrogenase activity in direct and reverse reactions spectrometrically by G. A. Kochetov’s method. Aldehyde dehydrogenase activity was examined by B. M. Kershnhots’s and E. V. Serkina’s methods, superoxide dismutase—by T. V. Sirota’s technology. Total protein level was examined by modified Louri’s method. The concentration of lactate was tested with the automatic analyzer “SuperGL Ambulance”. The indices of acidbase balance and blood gases partial pressure were estimated with special analyzer “ABL-77”. Additional control of energy metabolism changes was accomplished with derivative parameters, such as coefficient of energy reaction balance and coefficient of substrate provision. Different changes of blood physical and chemical parameters are induced by NO-processing which was fixed in our experiments. There is an inhibition of erythrocytes energy metabolism, decreasing of plasma antioxidant reserves, moderate ionic disorders and of acid-base misbalance in blood samples in vitro. Besides, according to the indirect signs, the used regimen of NO-processing mainly affected erythrocytes, and stipulated methemoglobin formation. These data testify that the used dose of gaseous nitric oxide is too high for investigated human blood. In our opinion, registered negative effects of free NO may be eliminated by bound nitric oxide use (first of all in its natural form—dinitrosyl-iron complexes).
文摘AIM:To study frequency of blood groups,prevalence of sickle-cell anemia trait and glucose-6-phosphate dehydrogenase deficiency(G6PD),among consanguineous Yansi tribe.METHODS:A total of 525 blood samples were collected,of which 256 among the Yansi population,and269 for the unrelated control group in the Bandunduprovince of Democratic Republic of Congo.Blood group antigens were determined in the following systems:ABO,Rh,Kell,Duffy,Kidd and MNS.Blood grouping and extended phenotype tests were performed according to standard immunohematological procedures.Spot tests and tandem mass spectrometry were used respectively for the assessment of G6PD and sickle-cell anemia trait.RESULTS:The frequency of ABO phenotypes conformed to the following order O>A>B>AB with notably 62.5%,23.8%,12.1%and 1.6%for the Yansi,and 54.6%,27.5%,14.1%and 3.7%for the unrelated control group,respectively(P=0.19).As for the Rh phenotypes,the most frequent were cc D.ee,cc D.Ee,Cc D.ee,corresponding to 71.5%,12.1%and 12.1%for the Yansi,and 70.6%,15.6%and 8.2%,for the unrelated control group(P=0.27).The frequency of MN and Ss phenotypes were statistically different between groups(P=0.0021 and P=0.0006).G6PD was observed in 11.3%of subjects in the Yansi group,and in 12.4%of controls(P=0.74).The sickle-cell anemia trait was present in 22.4%of Yansi subjects and 17.8%in the control group(P=0.24).Miscarriages and deaths in young age were more common among Yansi people.CONCLUSION:This study shows a significant difference in MNS blood group distribution between the Yansi tribe and a control population.The distribution of other blood groups and the prevalence of hemoglobinopathies did not differ in the Yansi tribe.
文摘目的初步探讨血镉及胎盘11β-羟基类固醇脱氢酶2(11β-hydroxysteroid dehydrogenase type 2,11β-HSD2)与重度子痫前期的相关性及镉与11β-HSD2参与重度子痫前期发生的机制。方法选取32例重度子痫前期妊娠孕妇为研究组及同期孕检正常孕妇32例为正常妊娠组,测定2组孕妇血镉水平和胎盘中11β-HSD2表达水平。结果与正常妊娠组相比,研究组重金属镉水平升高,11β-HSD2表达降低(P<0.05)。结论血镉与11β-HSD2可能参与了重度子痫前期的发生发展。
